Lundbeck breathes life into stranded molecule to treat new diseases

Drug candidate LU AG06466, which failed as a treatment for Tourette's, is the center of attention in two new phase I trials Lundbeck has launched this summer.
Photo: Lundbeck / PR
Photo: Lundbeck / PR

Lundbeck means business in picking drug candidate LU AG06466 back up again. The Danish pharmaceutical company is testing the drug in three phase I trials. In March 2020, it failed as a treatment for Tourette's syndrome in a phase II trial.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading